4-Chlorocinnamaldehyde

4-Chlorocinnamaldehyde (trans-p-Chlorocinnamaldehyde) is an antiviral agent. 4-Chlorocinnamaldehyde inhibits the replication of Coxsackievirus B3 in cardiomyocytes, but shows poor efficacy in animal experiments. 4-Chlorocinnamaldehyde can be used in studies related to viral myocarditis^[1]. In Vitro:4-Chlorocinnamaldehyde (Compound 2) (0.01-1000 μM; 72 h) shows no obvious cytotoxicity in neonatal rat cardiomyocytes, with a CC₅₀ of 6972.47 μM after 72 h of incubation^[1].
4-Chlorocinnamaldehyde (0.01-1000 μM; 72 h) weakly inhibits CVB3 replication in neonatal rat cardiomyocytes, with an IC₅₀ of 2109.08 μM and a therapeutic index of 3.31 after 72 h of incubation^[1].
4-Chlorocinnamaldehyde (10 μM; 72 h) inhibits the secretion of proinflammatory cytokines TNF-α, IL-1β and IL-6 induced by CVB3 in neonatal rat cardiomyocytes^[1].
4-Chlorocinnamaldehyde (10 μM; 12-24 h) inhibits the mRNA and protein expression of proinflammatory cytokines TNF-α, IL-1β and IL-6 in neonatal rat cardiomyocytes induced by CVB3^[1]. In Vivo:4-Chlorocinnamaldehyde (Compound 2) (20-60 mg/kg; p.o.; daily; 6 days) does not significantly reduce myocardial pathological scores or viral titers in Coxsackievirus B3-induced viral myocarditis in male BALB/c mice^[1].